

Special Issue

COVID-19 Vaccines: A Public Health Perspective

Message from the Guest Editors

The COVID-19 pandemic is a global crisis, with devastating health, social and economic impacts. Since December 2020, several vaccines against this disease have been progressively approved and distributed worldwide, opening the way to a gradual going back to pre-pandemic life. However, the issues related to these vaccines are still abundant and relevant from a Public Health viewpoint. They regard not only the efficacy and safety of vaccines and the duration of protection, but also the organization and overall impact of vaccination campaigns, the vaccination passports, the management of communication and many other aspects. The aim of this issue is to collect contributions on the different Public Health aspects related to COVID-19 vaccines to finally provide stakeholders with relevant evidences that could be useful for the decision-making process.

Guest Editors

Dr. Chiara de Waure

Dr. Aldo Rosano

Dr. Chiara Cadeddu

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/84391

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).